Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H C Meissner

Showing results (31-40 of 46) with videos related to

Pageof 5
Sort By:
The Pediatric Infectious Disease Journal|December 1, 1996
Prevention of respiratory syncytial virus infection in high risk infants: consensus opinion on the role of immunoprophylaxis with respiratory syncytial virus hyperimmune globulinH C Meissner, R C Welliver, S A Chartrand, et al.
Lancet (London, England)|December 4, 1993
Toxic shock syndrome toxin-secreting Staphylococcus aureus in Kawasaki syndromeD Y Leung, H C Meissner, D R Fulton, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 27, 2001
Meningococcal disease among children who live in a large metropolitan area, 1981-1996V J Wang, N Kuppermann, R Malley, et al.
The Journal of Pediatrics|October 27, 1998
Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. The Cardiac Study GroupE A Simoes, H M Sondheimer, F H Top, et al.
The Pediatric Infectious Disease Journal|March 27, 1999
Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: a consensus opinionH C Meissner, R C Welliver, S A Chartrand, et al.
Antimicrobial Agents and Chemotherapy|August 1, 1993
Controlled trial to evaluate protection of high-risk infants against respiratory syncytial virus disease by using standard intravenous immune globulinH C Meissner, D R Fulton, J R Groothuis, et al.
The Journal of Rheumatology|January 26, 1999
Report of the National Institutes of Health Workshop on Kawasaki DiseaseK S Barron, S T Shulman, A Rowley, et al.
The New England Journal of Medicine|June 30, 1994
Neonatal serologic screening and early treatment for congenital Toxoplasma gondii infection. The New England Regional Toxoplasma Working GroupN G Guerina, H W Hsu, H C Meissner, et al.
The Pediatric Infectious Disease Journal|January 1, 1995
Use of cytomegalovirus immunoglobulin in multiply transfused premature neonatesD R Snydman, B G Werner, H C Meissner, et al.
The New England Journal of Medicine|November 18, 1993
Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study GroupJ R Groothuis, E A Simoes, M J Levin, et al.
Pageof 5

Showing results (31-40 of 46) with videos related to

Sort By:
Pageof 5
The Pediatric Infectious Disease Journal|December 1, 1996
Prevention of respiratory syncytial virus infection in high risk infants: consensus opinion on the role of immunoprophylaxis with respiratory syncytial virus hyperimmune globulinH C Meissner, R C Welliver, S A Chartrand, et al.
Lancet (London, England)|December 4, 1993
Toxic shock syndrome toxin-secreting Staphylococcus aureus in Kawasaki syndromeD Y Leung, H C Meissner, D R Fulton, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 27, 2001
Meningococcal disease among children who live in a large metropolitan area, 1981-1996V J Wang, N Kuppermann, R Malley, et al.
The Journal of Pediatrics|October 27, 1998
Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. The Cardiac Study GroupE A Simoes, H M Sondheimer, F H Top, et al.
The Pediatric Infectious Disease Journal|March 27, 1999
Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: a consensus opinionH C Meissner, R C Welliver, S A Chartrand, et al.
Antimicrobial Agents and Chemotherapy|August 1, 1993
Controlled trial to evaluate protection of high-risk infants against respiratory syncytial virus disease by using standard intravenous immune globulinH C Meissner, D R Fulton, J R Groothuis, et al.
The Journal of Rheumatology|January 26, 1999
Report of the National Institutes of Health Workshop on Kawasaki DiseaseK S Barron, S T Shulman, A Rowley, et al.
The New England Journal of Medicine|June 30, 1994
Neonatal serologic screening and early treatment for congenital Toxoplasma gondii infection. The New England Regional Toxoplasma Working GroupN G Guerina, H W Hsu, H C Meissner, et al.
The Pediatric Infectious Disease Journal|January 1, 1995
Use of cytomegalovirus immunoglobulin in multiply transfused premature neonatesD R Snydman, B G Werner, H C Meissner, et al.
The New England Journal of Medicine|November 18, 1993
Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study GroupJ R Groothuis, E A Simoes, M J Levin, et al.
Pageof 5